Latham & Watkins LLP represented GSK in the transaction. Alector, Inc. and GlaxoSmithKline plc, announced a strategic global collaboration for the development and commercialization of two...
GlaxoSmithKline’s Collaboration with Alector
LegalZoom’s Initial Public Offering
Latham & Watkins LLP represented the underwriters in the offering. LegalZoom.com, Inc., a leading online platform for legal and compliance solutions in the United States, has...
Multi-Color Corporation’s Acquisition of Hexagon
Latham & Watkins LLP represented Multi-Color Corporation in the transaction. Multi-Color Corporation (MCC) and Hexagon Holdings (Hexagon) have signed a binding Sale and Purchase Agreement whereby MCC...
CVC Capital Partners’ Investment in Rayner
Latham & Watkins advised Rayner and Phoenix Equity Partners on the deal. CVC Capital Partners VIII announced today that it has agreed to acquire a majority...
FabricNano’s $12.5 Million Series A Funding
Latham & Watkins advised Atomico as lead investor in the Series A round of FabricNano. FabricNano raised US$12.5 million in its Series A financing round. FabricNano has developed a...
Fort Dearborn’s Merger With Multi-Color Corporation
Kirkland & Ellis advised Fort Dearborn, Debevoise & Plimpton LLP advised CD&R on the transaction, while Latham & Watkins LLP represented Platinum Equity and Multi-Color Corporation....
ICON’s Financings for the Acquisition of PRA Health Sciences
Cahill Gordon & Reindel LLP, Noerr and Schima Mayer Starlinger represented ICON in the transaction, while Latham & Watkins represented the lead arrangers and lenders, and...
Ro’s Acquisition of Kit
Latham & Watkins advised Ro in the transaction. Ro, the healthcare technology company, has announced the acquisition of at-home diagnostics company Kit. The acquisition expands the...
SentinelOne’s IPO and Concurrent Private Placement
Fenwick & West LLP advised SentinelOne on the deal, while Latham & Watkins LLP represents the underwriters. SentinelOne, an autonomous cybersecurity platform company, announced its initial public...
Zentalis Pharmaceuticals’ $150.4 Million Common Stock Offering
Latham & Watkins LLP represented Zentalis Pharmaceuticals in the offering. Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting...
Guala Closures S.p.A. ‘s €500 Million High Yield Bond Offering
IN BRIEF: Chiomenti, Kirkland & Ellis, Latham & Watkins, advised on the matter. Chiomenti advised Guala Closures with a team including Massimo Antonini (Tax Finance), Luca...
Sagard’s Acquisition of Ginger
IN BRIEF: Latham & Watkins, advised on the matter. Latham & Watkins advised Sagard Capital Partners LP with a team including Denis Criton (Picture – Corporate...